The latter report is important as the uniform behaviour of Tie2 in different disease settings (ovarian cancer and glioma) and between different VEGF pathway inhibitors (bevacizumab and cediranib) imply that this is a class-relevant finding that pertains to tumour vasculature in general rather than a particular disease type or specific anti-angiogenic treatment. Here, VEGFA is linked to neoplasm.